)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Spermosens
Spermosens (SPERM) investor relations material
Spermosens Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary7 May, 2026
Executive summary
Completed development of JUNO-Checked Generation 3, designed for high-volume clinical labs and initiated a new clinical validation study at RMC Malmö in Q2 2026, aiming for completion by year-end.
Advanced partnership discussions, signing MOUs with Sapyen and RSI to expand male fertility diagnostics in the US and internationally.
Commercial strategy remains partner-driven, focusing on license agreements as the primary revenue path.
Financial highlights
Net sales for Q1 2026 were SEK 0 thousand, unchanged year-over-year.
Operating loss for Q1 2026 was SEK -2,175 thousand, slightly higher than SEK -2,063 thousand in Q1 2025.
Cash and cash equivalents at quarter-end were SEK 4,481 thousand, down from SEK 13,147 thousand at Q1 2025.
Equity at period end was SEK 30,235 thousand, compared to SEK 38,100 thousand in Q1 2025.
Earnings per share for Q1 2026 was SEK -0.001, improved from SEK -0.002 in Q1 2025.
Outlook and guidance
Clinical validation of JUNO-Checked Generation 3 expected to complete by end of 2026.
Ambition to convert partnership discussions into formal agreements during 2026.
Financing runway expected through Q1 2027, with additional capital anticipated from TO6 warrants in late 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Spermosens
- Clinical validation and licensing targeted for 2026; strong partner interest and cost control.SPERM
Status update26 Mar 2026 - Patent wins, clinical validation, and strong cash position set stage for 2026 commercialization.SPERMQ4 202511 Feb 2026
- Clinical validation, patent wins, and strong liquidity support next-gen product launch plans.SPERMQ3 202512 Nov 2025
- Clinical validation and new funding support product development and market entry.SPERMQ2 202520 Aug 2025
- Clinical study progress, strategic partnerships, and capital raises drive Spermosens' 2024 outlook.SPERMQ3 202413 Jun 2025
- Operating loss narrows, but liquidity shortfall drives urgent capital raise and US expansion.SPERMQ2 202413 Jun 2025
- Positive clinical results and new funding position Spermosens for growth in fertility diagnostics.SPERMQ1 20256 Jun 2025
- Clinical progress and new partnerships drive outlook, but liquidity remains a key risk.SPERMQ4 20246 Jun 2025
Next Spermosens earnings date
Q2 202620 Aug, 2026
Spermosens
Next Spermosens earnings date
Q2 202620 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage